1516772-44-3 Usage
Description
AZ-27 is a complex organic compound with a unique molecular structure that exhibits various properties and potential applications across different industries. It is characterized by its ability to interact with other molecules and its potential as a therapeutic agent.
Uses
Used in Pharmaceutical Industry:
AZ-27 is used as a potential therapeutic agent for the treatment of respiratory syncytial virus (RSV) infections. It functions as an RNA polymerase inhibitor, targeting the virus's replication process and potentially limiting its spread within the host.
Used in Antiviral Applications:
AZ-27 is employed as an antiviral agent, particularly against respiratory syncytial virus (RSV). It works by inhibiting the viral RNA polymerase, which is essential for the virus's replication and propagation. This inhibition can help reduce the severity and duration of RSV infections, providing a valuable treatment option for patients.
Used in Drug Development:
In the field of drug development, AZ-27 serves as a promising candidate for further research and development. Its unique molecular structure and potential antiviral properties make it an interesting compound to explore for the creation of new medications targeting various viral infections.
Used in Research and Development:
AZ-27 is utilized in research and development settings to study its interactions with other molecules and its potential effects on various biological processes. This research can contribute to a better understanding of the compound's properties and its possible applications in medicine and other industries.
Enzyme inhibitor
This RSV inhibitor (FW = 633.77 g/mol) targets Respiratory Syncytial Virus, inhibiting both mRNA transcription and genome replication in cell based mini-genome assays, suggesting it targets a step common to both of these RNA synthesis processes. Analysis in an in vitro transcription run-on assay, containing RSV nucleocapsids, showed that AZ-27 inhibits (IC50 ≈ 15 nM) the synthesis of transcripts from the 3′-end of the genome to a greater extent than those from the 5′-end, indicating that it inhibits transcription initiation. In experiments assaying polymerase activity on the promoter, AZ-27 inhibits transcription and replication initiation. The RSV polymerase also utilizes the promoter sequence to perform a back-priming reaction. Addition of AZ-27 has no effect on the addition of up to three nucleotides by back-priming, but inhibits further extension of the back primed RNA. These findings suggest that the RSV polymerase is likely to adopt different conformations to execute its separate functions at the promoter.
Check Digit Verification of cas no
The CAS Registry Mumber 1516772-44-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,5,1,6,7,7 and 2 respectively; the second part has 2 digits, 4 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1516772-44:
(9*1)+(8*5)+(7*1)+(6*6)+(5*7)+(4*7)+(3*2)+(2*4)+(1*4)=173
173 % 10 = 3
So 1516772-44-3 is a valid CAS Registry Number.
1516772-44-3Relevant articles and documents
Discovery of a potent respiratory syncytial virus RNA polymerase inhibitor
Xiong, Hui,Foulk, Melinda,Aschenbrenner, Lisa,Fan, Jun,Tiong-Yip, Choi-Lai,Johnson, Kenneth D.,Moustakas, Demetri,Fleming, Paul R.,Brown, Dean G.,Zhang, Minli,Ferguson, Douglas,Wu, Dedong,Yu, Qin
, p. 6789 - 6793 (2013)
Targeting viral polymerases has been a proven and attractive strategy for antiviral drug discovery. Herein we describe our effort in improving the antiviral activity and physical properties of a series of benzothienoazepine compounds as respiratory syncyt
